{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T03:51:54Z","timestamp":1768621914865,"version":"3.49.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"DOI":"10.1186\/s12916-025-04004-2","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T05:07:09Z","timestamp":1743224829000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Exploratory analysis of the relationship between striatal connectivity and apathy during phosphodiesterase 10 inhibition in schizophrenia: findings from a randomized crossover trial"],"prefix":"10.1186","volume":"23","author":[{"given":"Wolfgang","family":"Omlor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giacomo","family":"Cecere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gao-Yang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"Spiller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akhil Ratan","family":"Misra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Finn","family":"Rabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nils","family":"Kallen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Kirschner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Werner","family":"Surbeck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Achim","family":"Burrer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Garibaldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0160tefan","family":"Holiga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juergen","family":"Dukart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Umbricht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Homan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,28]]},"reference":[{"key":"4004_CR1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.schres.2023.07.010","volume":"258","author":"SR Marder","year":"2023","unstructured":"Marder SR, Umbricht D. Negative symptoms in schizophrenia: newly emerging measurements, pathways, and treatments. Schizophr Res. 2023;258:71\u20137.","journal-title":"Schizophr Res"},{"key":"4004_CR2","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1093\/schbul\/sbu170","volume":"41","author":"P Fusar-Poli","year":"2015","unstructured":"Fusar-Poli P, Papanastasiou E, Stahl D, Rocchetti M, Carpenter W, Shergill S, McGuire P. Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials. Schizophr Bull. 2015;41:892\u20139.","journal-title":"Schizophr Bull"},{"key":"4004_CR3","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.2147\/NDT.S201726","volume":"15","author":"G Cerveri","year":"2019","unstructured":"Cerveri G, Gesi C, Mencacci C. Pharmacological treatment of negative symptoms in schizophrenia: update and proposal of a clinical algorithm. Neuropsychiatr Dis Treat. 2019;15:1525\u201335.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"4004_CR4","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(21)01730-X","volume":"399","author":"S Jauhar","year":"2022","unstructured":"Jauhar S, Johnstone M, McKenna PJ. Schizophrenia. Lancet. 2022;399:473\u201386.","journal-title":"Lancet"},{"key":"4004_CR5","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1093\/schbul\/sbj013","volume":"32","author":"JJ Blanchard","year":"2006","unstructured":"Blanchard JJ, Cohen AS. The structure of negative symptoms within schizophrenia: implications for assessment. Schizophr Bull. 2006;32:238\u201345.","journal-title":"Schizophr Bull"},{"key":"4004_CR6","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/S2215-0366(18)30050-6","volume":"5","author":"S Galderisi","year":"2018","unstructured":"Galderisi S, Mucci A, Buchanan RW, Arango C. Negative symptoms of schizophrenia: new developments and unanswered research questions. Lancet Psychiatry. 2018;5:664\u201377.","journal-title":"Lancet Psychiatry"},{"issue":"Suppl 1","key":"4004_CR7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4088\/JCP.13049su1c.01","volume":"75","author":"B Kirkpatrick","year":"2014","unstructured":"Kirkpatrick B. Developing concepts in negative symptoms: primary vs secondary and apathy vs expression. J Clin Psychiatry. 2014;75(Suppl 1):3\u20137.","journal-title":"J Clin Psychiatry"},{"key":"4004_CR8","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.neubiorev.2020.06.004","volume":"116","author":"I Begue","year":"2020","unstructured":"Begue I, Kaiser S, Kirschner M. Pathophysiology of negative symptom dimensions of schizophrenia - current developments and implications for treatment. Neurosci Biobehav Rev. 2020;116:74\u201388.","journal-title":"Neurosci Biobehav Rev"},{"key":"4004_CR9","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.schres.2011.06.030","volume":"132","author":"WP Horan","year":"2011","unstructured":"Horan WP, Kring AM, Gur RE, Reise SP, Blanchard JJ. Development and psychometric validation of the Clinical Assessment Interview for Negative Symptoms (CAINS). Schizophr Res. 2011;132:140\u20135.","journal-title":"Schizophr Res"},{"key":"4004_CR10","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/schbul\/sbq059","volume":"37","author":"B Kirkpatrick","year":"2011","unstructured":"Kirkpatrick B, Strauss GP, Nguyen L, Fischer BA, Daniel DG, Cienfuegos A, Marder SR. The brief negative symptom scale: psychometric properties. Schizophr Bull. 2011;37:300\u20135.","journal-title":"Schizophr Bull"},{"key":"4004_CR11","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1001\/jamapsychiatry.2018.2475","volume":"75","author":"GP Strauss","year":"2018","unstructured":"Strauss GP, Nunez A, Ahmed AO, Barchard KA, Granholm E, Kirkpatrick B, Gold JM, Allen DN. The latent structure of negative symptoms in schizophrenia. JAMA Psychiat. 2018;75:1271\u20139.","journal-title":"JAMA Psychiat"},{"key":"4004_CR12","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.biopsych.2016.05.021","volume":"81","author":"TV Maia","year":"2017","unstructured":"Maia TV, Frank MJ. An integrative perspective on the role of dopamine in schizophrenia. Biol Psychiatry. 2017;81:52\u201366.","journal-title":"Biol Psychiatry"},{"issue":"Suppl 2","key":"4004_CR13","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1093\/schbul\/sbt197","volume":"40","author":"GP Strauss","year":"2014","unstructured":"Strauss GP, Waltz JA, Gold JM. A review of reward processing and motivational impairment in schizophrenia. Schizophr Bull. 2014;40(Suppl 2):S107-116.","journal-title":"Schizophr Bull"},{"key":"4004_CR14","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.euroneuro.2013.06.007","volume":"24","author":"AM Kring","year":"2014","unstructured":"Kring AM, Barch DM. The motivation and pleasure dimension of negative symptoms: neural substrates and behavioral outputs. Eur Neuropsychopharmacol. 2014;24:725\u201336.","journal-title":"Eur Neuropsychopharmacol"},{"key":"4004_CR15","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1503\/jpn.140383","volume":"41","author":"M Kirschner","year":"2016","unstructured":"Kirschner M, Hager OM, Bischof M, Hartmann MN, Kluge A, Seifritz E, Tobler PN, Kaiser S. Ventral striatal hypoactivation is associated with apathy but not diminished expression in patients with schizophrenia. J Psychiatry Neurosci. 2016;41:152\u201361.","journal-title":"J Psychiatry Neurosci"},{"key":"4004_CR16","first-page":"460","volume":"1","author":"EC Dowd","year":"2016","unstructured":"Dowd EC, Frank MJ, Collins A, Gold JM, Barch DM. Probabilistic reinforcement learning in patients with schizophrenia: relationships to anhedonia and avolition. Biol Psychiatry Cogn Neurosci Neuroimaging. 2016;1:460\u201373.","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"key":"4004_CR17","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1001\/archgenpsychiatry.2011.1269","volume":"69","author":"JM Gold","year":"2012","unstructured":"Gold JM, Waltz JA, Matveeva TM, Kasanova Z, Strauss GP, Herbener ES, Collins AG, Frank MJ. Negative symptoms and the failure to represent the expected reward value of actions: behavioral and computational modeling evidence. Arch Gen Psychiatry. 2012;69:129\u201338.","journal-title":"Arch Gen Psychiatry"},{"key":"4004_CR18","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.biopsych.2006.09.042","volume":"62","author":"JA Waltz","year":"2007","unstructured":"Waltz JA, Frank MJ, Robinson BM, Gold JM. Selective reinforcement learning deficits in schizophrenia support predictions from computational models of striatal-cortical dysfunction. Biol Psychiatry. 2007;62:756\u201364.","journal-title":"Biol Psychiatry"},{"key":"4004_CR19","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.biopsych.2012.12.022","volume":"74","author":"JM Gold","year":"2013","unstructured":"Gold JM, Strauss GP, Waltz JA, Robinson BM, Brown JK, Frank MJ. Negative symptoms of schizophrenia are associated with abnormal effort-cost computations. Biol Psychiatry. 2013;74:130\u20136.","journal-title":"Biol Psychiatry"},{"key":"4004_CR20","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/schbul\/sbu102","volume":"41","author":"MN Hartmann","year":"2015","unstructured":"Hartmann MN, Hager OM, Reimann AV, Chumbley JR, Kirschner M, Seifritz E, Tobler PN, Kaiser S. Apathy but not diminished expression in schizophrenia is associated with discounting of monetary rewards by physical effort. Schizophr Bull. 2015;41:503\u201312.","journal-title":"Schizophr Bull"},{"key":"4004_CR21","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/7854_2015_385","volume":"27","author":"JA Waltz","year":"2016","unstructured":"Waltz JA, Gold JM. Motivational deficits in schizophrenia and the representation of expected value. Curr Top Behav Neurosci. 2016;27:375\u2013410.","journal-title":"Curr Top Behav Neurosci"},{"key":"4004_CR22","first-page":"280","volume":"4","author":"D Hernaus","year":"2019","unstructured":"Hernaus D, Frank MJ, Brown EC, Brown JK, Gold JM, Waltz JA. Impaired expected value computations in schizophrenia are associated with a reduced ability to integrate reward probability and magnitude of recent outcomes. Biol Psychiatry Cogn Neurosci Neuroimaging. 2019;4:280\u201390.","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"key":"4004_CR23","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.bpsgos.2021.03.001","volume":"1","author":"D Umbricht","year":"2021","unstructured":"Umbricht D, Abt M, Tamburri P, Chatham C, Holiga S, Frank MJ, Collins AGE, Walling DP, Mofsen R, Gruener D, Gertsik L, Sevigny J, Keswani S, Dukart J. Proof-of-mechanism study of the phosphodiesterase 10 inhibitor RG7203 in patients with schizophrenia and negative symptoms. Biol Psychiatry Glob Open Sci. 2021;1:70\u20137.","journal-title":"Biol Psychiatry Glob Open Sci"},{"key":"4004_CR24","doi-asserted-by":"crossref","unstructured":"Umbricht D, Dukart J, Abt M, Tamburri P, Chatham C, Frank M, Collins A, Walling D, Mofsen R, Gertsik L, Park L, Sevigny J. T187. A proof-of-mechanism study of the PDE10 inhibitor RG7203 in patients with schizophrenia and negative symptoms probing reward functions with imaging and behavioral approaches. In: ACNP 56th Annual Meeting, December 3\u20137, Palm Springs, California Neuropsychopharmacology, Supplement, S415. 2017.","DOI":"10.1093\/schbul\/sby018.830"},{"key":"4004_CR25","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/00004714-199906000-00003","volume":"19","author":"JG Ramaekers","year":"1999","unstructured":"Ramaekers JG, Louwerens JW, Muntjewerff ND, Milius H, de Bie A, Rosenzweig P, Patat A, O\u2019Hanlon JF. Psychomotor, cognitive, extrapyramidal, and affective functions of healthy volunteers during treatment with an atypical (amisulpride) and a classic (haloperidol) antipsychotic. J Clin Psychopharmacol. 1999;19:209\u201321.","journal-title":"J Clin Psychopharmacol"},{"key":"4004_CR26","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.schres.2016.05.003","volume":"186","author":"M Kirschner","year":"2017","unstructured":"Kirschner M, Aleman A, Kaiser S. Secondary negative symptoms - a review of mechanisms, assessment and treatment. Schizophr Res. 2017;186:29\u201338.","journal-title":"Schizophr Res"},{"key":"4004_CR27","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1093\/cercor\/bhn041","volume":"18","author":"A Di Martino","year":"2008","unstructured":"Di Martino A, Scheres A, Margulies DS, Kelly AM, Uddin LQ, Shehzad Z, Biswal B, Walters JR, Castellanos FX, Milham MP. Functional connectivity of human striatum: a resting state FMRI study. Cereb Cortex. 2008;18:2735\u201347.","journal-title":"Cereb Cortex"},{"key":"4004_CR28","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1001\/jamapsychiatry.2013.1976","volume":"70","author":"A Fornito","year":"2013","unstructured":"Fornito A, Harrison BJ, Goodby E, Dean A, Ooi C, Nathan PJ, Lennox BR, Jones PB, Suckling J, Bullmore ET. Functional dysconnectivity of corticostriatal circuitry as a risk phenotype for psychosis. JAMA Psychiat. 2013;70:1143\u201351.","journal-title":"JAMA Psychiat"},{"key":"4004_CR29","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1001\/jamapsychiatry.2014.1734","volume":"72","author":"DK Sarpal","year":"2015","unstructured":"Sarpal DK, Robinson DG, Lencz T, Argyelan M, Ikuta T, Karlsgodt K, Gallego JA, Kane JM, Szeszko PR, Malhotra AK. Antipsychotic treatment and functional connectivity of the striatum in first-episode schizophrenia. JAMA Psychiat. 2015;72:5\u201313.","journal-title":"JAMA Psychiat"},{"key":"4004_CR30","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1038\/s41386-019-0464-y","volume":"44","author":"P Homan","year":"2019","unstructured":"Homan P, Argyelan M, Fales CL, Barber AD, DeRosse P, Szeszko PR, Robinson DG, Lencz T, Malhotra AK. Striatal volume and functional connectivity correlate with weight gain in early-phase psychosis. Neuropsychopharmacology. 2019;44:1948\u201354.","journal-title":"Neuropsychopharmacology"},{"key":"4004_CR31","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41591-020-0793-8","volume":"26","author":"A Li","year":"2020","unstructured":"Li A, Zalesky A, Yue W, Howes O, Yan H, Liu Y, Fan L, Whitaker KJ, Xu K, Rao G, Li J, Liu S, Wang M, Sun Y, Song M, Li P, Chen J, Chen Y, Wang H, Liu W, Li Z, Yang Y, Guo H, Wan P, Lv L, Lu L, Yan J, Song Y, Wang H, Zhang H, Wu H, Ning Y, Du Y, Cheng Y, Xu J, Xu X, Zhang D, Wang X, Jiang T, Liu B. A neuroimaging biomarker for striatal dysfunction in schizophrenia. Nat Med. 2020;26:558\u201365.","journal-title":"Nat Med"},{"key":"4004_CR32","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.biopsych.2022.07.017","volume":"93","author":"K Sabaroedin","year":"2023","unstructured":"Sabaroedin K, Tiego J, Fornito A. Circuit-based approaches to understanding corticostriatothalamic dysfunction across the psychosis continuum. Biol Psychiatry. 2023;93:113\u201324.","journal-title":"Biol Psychiatry"},{"key":"4004_CR33","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1093\/schbul\/sby165","volume":"45","author":"DK Shukla","year":"2019","unstructured":"Shukla DK, Chiappelli JJ, Sampath H, Kochunov P, Hare SM, Wisner K, Rowland LM, Hong LE. Aberrant frontostriatal connectivity in negative symptoms of schizophrenia. Schizophr Bull. 2019;45:1051\u20139.","journal-title":"Schizophr Bull"},{"key":"4004_CR34","doi-asserted-by":"crossref","first-page":"e0621232024","DOI":"10.1523\/JNEUROSCI.0621-23.2024","volume":"44","author":"R Pedersen","year":"2024","unstructured":"Pedersen R, Johansson J, Nordin K, Rieckmann A, Wahlin A, Nyberg L, Backman L, Salami A. Dopamine D1-receptor organization contributes to functional brain architecture. J Neurosci. 2024;44:e0621232024.","journal-title":"J Neurosci"},{"key":"4004_CR35","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/s42003-022-03434-5","volume":"5","author":"P Manza","year":"2022","unstructured":"Manza P, Shokri-Kojori E, Demiral SB, Wiers CE, Zhang R, Giddens N, McPherson K, Biesecker E, Dennis E, Johnson A, Tomasi D, Wang GJ, Volkow ND. Cortical D1 and D2 dopamine receptor availability modulate methylphenidate-induced changes in brain activity and functional connectivity. Commun Biol. 2022;5:514.","journal-title":"Commun Biol"},{"key":"4004_CR36","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbas.2023.100079","volume":"3","author":"R Pedersen","year":"2023","unstructured":"Pedersen R, Johansson J, Salami A. Dopamine D1-signaling modulates maintenance of functional network segregation in aging. Aging Brain. 2023;3: 100079.","journal-title":"Aging Brain"},{"key":"4004_CR37","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1093\/cercor\/bhs136","volume":"23","author":"DM Cole","year":"2013","unstructured":"Cole DM, Oei NY, Soeter RP, Both S, van Gerven JM, Rombouts SA, Beckmann CF. Dopamine-dependent architecture of cortico-subcortical network connectivity. Cereb Cortex. 2013;23:1509\u201316.","journal-title":"Cereb Cortex"},{"key":"4004_CR38","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.neuroimage.2011.07.086","volume":"59","author":"PC Tu","year":"2012","unstructured":"Tu PC, Hsieh JC, Li CT, Bai YM, Su TP. Cortico-striatal disconnection within the cingulo-opercular network in schizophrenia revealed by intrinsic functional connectivity analysis: a resting fMRI study. Neuroimage. 2012;59:238\u201347.","journal-title":"Neuroimage"},{"key":"4004_CR39","doi-asserted-by":"crossref","first-page":"538","DOI":"10.4088\/JCP.v58n1205","volume":"58","author":"SR Marder","year":"1997","unstructured":"Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry. 1997;58:538\u201346.","journal-title":"J Clin Psychiatry"},{"key":"4004_CR40","doi-asserted-by":"crossref","DOI":"10.56441\/hilbertpress.2246.5840","volume-title":"CONN functional connectivity toolbox: RRID SCR_009550, release 22","author":"A Nieto-Castanon","year":"2022","unstructured":"Nieto-Castanon A, Whitfield-Gabrieli S. CONN functional connectivity toolbox: RRID SCR_009550, release 22. Boston, MA: Hilbert Press; 2022."},{"key":"4004_CR41","doi-asserted-by":"crossref","first-page":"3","DOI":"10.56441\/hilbertpress.2207.6599","volume-title":"Handbook of functional connectivity magnetic resonance imaging methods in CONN","author":"A Nieto-Castanon","year":"2020","unstructured":"Nieto-Castanon A. Handbook of functional connectivity magnetic resonance imaging methods in CONN. Boston: Hilbert Press; 2020. p. 3\u201316, 17\u201325."},{"key":"4004_CR42","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jpsychires.2021.03.041","volume":"138","author":"SS Gangadin","year":"2021","unstructured":"Gangadin SS, Cahn W, Scheewe TW, Hulshoff Pol HE, Bossong MG. Reduced resting state functional connectivity in the hippocampus-midbrain-striatum network of schizophrenia patients. J Psychiatr Res. 2021;138:83\u20138.","journal-title":"J Psychiatr Res"},{"key":"4004_CR43","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1038\/nn.4438","volume":"19","author":"MR Delgado","year":"2016","unstructured":"Delgado MR, Beer JS, Fellows LK, Huettel SA, Platt ML, Quirk GJ, Schiller D. Viewpoints: dialogues on the functional role of the ventromedial prefrontal cortex. Nat Neurosci. 2016;19:1545\u201352.","journal-title":"Nat Neurosci"},{"key":"4004_CR44","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1177\/1550059417745934","volume":"49","author":"A Amodio","year":"2018","unstructured":"Amodio A, Quarantelli M, Mucci A, Prinster A, Soricelli A, Vignapiano A, Giordano GM, Merlotti E, Nicita A, Galderisi S. Avolition-apathy and white matter connectivity in schizophrenia: reduced fractional anisotropy between amygdala and insular cortex. Clin EEG Neurosci. 2018;49:55\u201365.","journal-title":"Clin EEG Neurosci"},{"key":"4004_CR45","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1093\/schbul\/sbaa092","volume":"47","author":"X Duan","year":"2021","unstructured":"Duan X, He C, Ou J, Wang R, Xiao J, Li L, Wu R, Zhang Y, Zhao J, Chen H. Reduced hippocampal volume and its relationship with verbal memory and negative symptoms in treatment-naive first-episode adolescent-onset schizophrenia. Schizophr Bull. 2021;47:64\u201374.","journal-title":"Schizophr Bull"},{"key":"4004_CR46","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1037\/abn0000461","volume":"128","author":"EK Moran","year":"2019","unstructured":"Moran EK, Culbreth AJ, Kandala S, Barch DM. From neuroimaging to daily functioning: a multimethod analysis of reward anticipation in people with schizophrenia. J Abnorm Psychol. 2019;128:723\u201334.","journal-title":"J Abnorm Psychol"},{"key":"4004_CR47","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1192\/bjp.bp.114.151928","volume":"210","author":"H Peters","year":"2017","unstructured":"Peters H, Riedl V, Manoliu A, Scherr M, Schwerthoffer D, Zimmer C, Forstl H, Bauml J, Sorg C, Koch K. Changes in extra-striatal functional connectivity in patients with schizophrenia in a psychotic episode. Br J Psychiatry. 2017;210:75\u201382.","journal-title":"Br J Psychiatry"},{"key":"4004_CR48","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2202-11-5","volume":"11","author":"SE Lazic","year":"2010","unstructured":"Lazic SE. The problem of pseudoreplication in neuroscientific studies: is it affecting your analysis? BMC Neurosci. 2010;11: 5.","journal-title":"BMC Neurosci"},{"key":"4004_CR49","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S1364-6613(00)01483-2","volume":"4","author":"G Bush","year":"2000","unstructured":"Bush G, Luu P, Posner MI. Cognitive and emotional influences in anterior cingulate cortex. Trends Cogn Sci. 2000;4:215\u201322.","journal-title":"Trends Cogn Sci"},{"key":"4004_CR50","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1073\/pnas.012470999","volume":"99","author":"G Bush","year":"2002","unstructured":"Bush G, Vogt BA, Holmes J, Dale AM, Greve D, Jenike MA, Rosen BR. Dorsal anterior cingulate cortex: a role in reward-based decision making. Proc Natl Acad Sci U S A. 2002;99:523\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4004_CR51","doi-asserted-by":"crossref","first-page":"7","DOI":"10.31887\/DCNS.2016.18.1\/shaber","volume":"18","author":"SN Haber","year":"2016","unstructured":"Haber SN. Corticostriatal circuitry. Dialogues Clin Neurosci. 2016;18:7\u201321.","journal-title":"Dialogues Clin Neurosci"},{"key":"4004_CR52","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1038\/nn.4384","volume":"19","author":"A Shenhav","year":"2016","unstructured":"Shenhav A, Cohen JD, Botvinick MM. Dorsal anterior cingulate cortex and the value of control. Nat Neurosci. 2016;19:1286\u201391.","journal-title":"Nat Neurosci"},{"key":"4004_CR53","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.schres.2016.10.004","volume":"186","author":"L Deserno","year":"2017","unstructured":"Deserno L, Heinz A, Schlagenhauf F. Computational approaches to schizophrenia: a perspective on negative symptoms. Schizophr Res. 2017;186:46\u201354.","journal-title":"Schizophr Res"},{"key":"4004_CR54","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1037\/abn0000164","volume":"125","author":"AJ Culbreth","year":"2016","unstructured":"Culbreth AJ, Westbrook A, Daw ND, Botvinick M, Barch DM. Reduced model-based decision-making in schizophrenia. J Abnorm Psychol. 2016;125:777\u201387.","journal-title":"J Abnorm Psychol"},{"key":"4004_CR55","doi-asserted-by":"crossref","first-page":"13684","DOI":"10.1038\/s41598-022-17557-6","volume":"12","author":"D Fedeli","year":"2022","unstructured":"Fedeli D, Del Maschio N, Del Mauro G, Defendenti F, Sulpizio S, Abutalebi J. Cingulate cortex morphology impacts on neurofunctional activity and behavioral performance in interference tasks. Sci Rep. 2022;12:13684.","journal-title":"Sci Rep"},{"key":"4004_CR56","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.neuropsychologia.2017.07.003","volume":"118","author":"C Le Heron","year":"2018","unstructured":"Le Heron C, Apps MAJ, Husain M. The anatomy of apathy: a neurocognitive framework for amotivated behaviour. Neuropsychologia. 2018;118:54\u201367.","journal-title":"Neuropsychologia"},{"key":"4004_CR57","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.tins.2018.12.004","volume":"42","author":"RA McCutcheon","year":"2019","unstructured":"McCutcheon RA, Abi-Dargham A, Howes OD. Schizophrenia, dopamine and the striatum: from biology to symptoms. Trends Neurosci. 2019;42:205\u201320.","journal-title":"Trends Neurosci"},{"key":"4004_CR58","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1001\/jamapsychiatry.2019.3360","volume":"77","author":"RA McCutcheon","year":"2020","unstructured":"McCutcheon RA, Reis Marques T, Howes OD. Schizophrenia-an overview. JAMA Psychiatry. 2020;77:201\u201310.","journal-title":"JAMA Psychiatry"},{"key":"4004_CR59","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S2215-0366(21)00386-2","volume":"9","author":"D Bugarski-Kirola","year":"2022","unstructured":"Bugarski-Kirola D, Arango C, Fava M, Nasrallah H, Liu IY, Abbs B, Stankovic S. Pimavanserin for negative symptoms of schizophrenia: results from the ADVANCE phase 2 randomised, placebo-controlled trial in North America and Europe. Lancet Psychiatry. 2022;9:46\u201358.","journal-title":"Lancet Psychiatry"},{"key":"4004_CR60","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJMoa2017015","volume":"384","author":"SK Brannan","year":"2021","unstructured":"Brannan SK, Sawchak S, Miller AC, Lieberman JA, Paul SM, Breier A. Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia. N Engl J Med. 2021;384:717\u201326.","journal-title":"N Engl J Med"},{"key":"4004_CR61","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuroimage.2019.116157","volume":"203","author":"S Noble","year":"2019","unstructured":"Noble S, Scheinost D, Constable RT. A decade of test-retest reliability of functional connectivity: a systematic review and meta-analysis. Neuroimage. 2019;203: 116157.","journal-title":"Neuroimage"},{"key":"4004_CR62","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1162\/netn_a_00148","volume":"4","author":"L Tozzi","year":"2020","unstructured":"Tozzi L, Fleming SL, Taylor ZD, Raterink CD, Williams LM. Test-retest reliability of the human functional connectome over consecutive days: identifying highly reliable portions and assessing the impact of methodological choices. Netw Neurosci. 2020;4:925\u201345.","journal-title":"Netw Neurosci"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-04004-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-025-04004-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-04004-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T05:09:44Z","timestamp":1743224984000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-025-04004-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,28]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4004"],"URL":"https:\/\/doi.org\/10.1186\/s12916-025-04004-2","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,28]]},"assertion":[{"value":"8 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The following ethics committees approved the experiments: Copernicus Group IRB, P.O. Box 110605, Research Triangle Park, NC 27709, approval given on May 27th 2016; Washington University in St. Louis, Human Protection Office, 660 South Euclid Ave., Campus Box 8089, St. Louis, MO 63110, approval given on 5th August 2016; Alpha IRB, 1001 Avenida Pico, Suite C#497, San Clemente, CA 92673, approval given on 8th July 2016; Integ Review IRB, 3815 S. Capital of Texas Hwy, Suite 320, Austin, TX 78704, approval given on 27th May 2016. Informed consent to participate in the study was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Co-author D. Umbricht is owner of xperimed LLC that provides consultation on all aspects of clinical drug development for neuropsychiatric indications, works on a contracting basis for Autifony Therapeutics and Gilgamesh pharmaceuticals and holds stocks of Roche, Novartis and Gilgamesh Pharmaceuticals. He has been consulting to Abbvie, Biogen, ERG, Forbion, Healthrhyhms, Kynexis, Psychogenic, Roche and Siesta. Co-author D. Umbricht was a full-time employee of F. Hoffmann-La Roche Ltd., which held the license for RG7203 during the study period. Co-author \u0160. Holiga is a full-time employee of F. Hoffmann-La Roche Ltd. Co-author G. Garibaldi is the chief medical officer of Noema, which currently holds the license for RG7203, and advisor of Retrotope. P. Homan has received grants and honoraria from Novartis, Lundbeck, Mepha, Janssen, Boehringer Ingelheim, Neurolite outside of this work. No further disclosures were reported.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"187"}}